Mytos

Mytos automates production of stem cell-derived therapies - enabling them to scale to millions of patients at low cost. Our custom iDEM robotics platform powers our automated CDMO. Our announced partnerships include neurons for treating Parkinson's, bone for bone repair, corneal cells for blindness, and auditory neurons for hearing loss (and we have more to announce). Cells produced on our iDEM platform will be going into patients by 2027. Mytos has raised over $24m from leading investors, including YCombinator, Buckley Ventures and IQ Capital - as well as founders and execs from companies like Kite, Sana, Dropbox, and Revolut. Our team is made up of brilliant engineers from companies like Dyson and Autodesk - working hand-in-hand with Nature-published scientists. We're hiring now - visit our website to see open positions